Relvar for patients not well controlled
PRD with Relvar may be able to help patients like Oscar and Paula achieve asthma control.2
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
An estimated 71% of patients with asthma remain uncontrolled despite treatment.2
The problem lies with many asthma patients overperceiving their level of asthma control when, upon deeper discussion, their symptoms often turn out to be frequent and regular.1
When asked ‘overall, how would you describe the control you generally have over your asthma?’,
When asked ‘and how satisfied or unsatisfied would you say you are with the level of control you currently have over your asthma?’,
Day-time symptoms were defined as any asthma-related symptoms during the day time
Night-time symptoms were defined as waking up at night or difficulty sleeping
Hypothetical patient used for illustrative purposes
“I’m fine. I still go out with my friends. It’s just that often I have to go home early, because I get tired from waking up some nights short of breath.”
According to GINA,3 Paula is partially controlled, with two night-time awakenings in the past month.
Hypothetical patient used for illustrative purposes
“I think I’m okay. I keep active, but I guess I don’t exercise as much as I used to… and I tend to take the lift instead of the stairs. I just hate having to interrupt what I’m doing to take my reliever all the time.”
According to GINA,3 Oscar has uncontrolled asthma: in the last month he has been avoiding physical activity, and has been using his reliever 3 times a week because of his day-time symptoms.
See how GINA defines asthma control here.
Abbreviations
GINA, Global Initiative for Asthma.
RELVAR Ellipta was created in collaboration with
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Relvar is a registered trademark of the GlaxoSmithKline group of companies
PM-IE-FFV-WCNT-230006 January 2024